恩替卡韦治疗乙型肝炎的疗效及安全性

恩替卡韦是一种有效的、选择性抑制乙型肝炎病毒复制的脱氧鸟嘌呤核苷类似物,由Bristol MyersSquibb公司研究开发,用于治疗乙型肝炎。体外试验表明,恩替卡韦比其他核苷类似物更有效。动物模型和人体临床研究结果显示,恩替卡韦具有极强的抑制乙型肝炎病毒复制,降低血清病毒DNA水平的作用,对耐拉米夫定的突变病毒株仍然有效,且未见明显的不良反应和线粒体毒性。

Efficacy and safety of entecavir on hepatitis B

Entecavir, a new deoxyguanine nucleoside analogue, is a effective selective inhibitor of the replication of hepatitis B virus. It has been developed as an anti-hepatitis B virus agent for treatment of chronic hepatitis B virus infection by Bristol-Myers Squibb Company. In vitro this compound has been proved to be far more effective than other nucleoside analogue. In animal models and clinical studies, entecavir revealed impressive reduction of serum viral DNA and excellent suppression of hepatitis B virus replication without significant side effects or evidence of mitochondrial toxicity. Until now, no entecavir-resistant viral mutants have been described and thus further positive response is foreseen in the future.